Definitive Contract 75N93025C00009
Award Date
11/15/24
Potential Completion Date
11/14/25
Potential Value
$307K
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Doylestown, PA 18901, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Definitive Contract to CFD Research Corporation, a for-profit organization, to perform Phase I SBIR research on a "SMART BIOREACTOR FOR LARGE-SCALE HIGH TITER PHAGE PREPS" project. The contract has a potential value of $299,946.26 and a completion date of August 15, 2022. This SBIR award was not set aside for a specific business...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $49,946.10 firm-fixed-price purchase order contract for antibody expression services to Biointron Biological USA Inc., a small disadvantaged business. The contract, which has no set-aside designation, has an ultimate completion date of July 11, 2025. The award was made on July 12, 2024. NIAID is responsible for conducting and supporting research to understand, treat, and prevent infectious and...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a Firm Fixed Price Purchase Order contract to Asischem Inc. to provide custom synthesis of a chemical compound. The contract, valued at $4,890.00, was awarded on August 3, 2015 with a completion date of December 1, 2015. This contract was not set aside for any specific business type or size. Based on the agency name, this contract is likely related to NIAID's research and development programs focused on infectious...
This $1,797,717.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Intralytix Inc., a biotechnology company specializing in bacteriophage-based products. The contract is for the development of a "Universal, Scalable Artificial Intelligence-Based Platform for Manufacturing High Titer Biopharmaceuticals", which aligns with...
The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $300,000 firm fixed price definitive contract to Nference Inc., a for-profit organization located in Cambridge, Massachusetts, to deliver on SBIR Topic 111 with a completion date of September 15, 2023. No set-aside designation was used for this award. The contract will support the National Institute of Allergy and Infectious Diseases' mission to conduct and...
This is a $299,208 firm fixed price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to John Snow Labs Inc., a self-certified small disadvantaged business. The contract is for SBIR Topic 135, with a period of performance through September 4, 2025. The contract does not have a set-aside designation. As an SBIR (Small Business Innovation Research) contract, it is part of a larger SBIR program managed by NIAID to fund research and...
This federal contract award was issued by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Pharmacology Discovery Services Taiwan, Ltd., a Taiwanese for-profit organization. The contract, valued at $1,797,620.00, is a delivery order issued under the larger NIAID Preclinical Models of Infectious Diseases 2017-2024 indefinite-delivery/indefinite-quantity contract vehicle. Under this contract,...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $18,523,063.00 definitive cost-plus-fixed-fee contract to Blacksmith Medicines, Inc. (doing business as Forge Therapeutics) for the development of a first-in-class LPXC inhibitor to treat multidrug-resistant gram-negative urinary tract infections. The contract, which has no set-aside designation, was awarded under NIAID's Omnibus Broad Agency Announcement seeking...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $332,878 delivery order to Pharmacology Discovery Services Taiwan, LTD under the NIAID Preclinical Models of Infectious Diseases 2017-2024 master IDIQ. This cost-plus-award-fee contract will provide pre-clinical models of infectious diseases to support research efforts at NIAID through September 1, 2021. As part of its mission to conduct and support research on infectious, immunologic, and...